Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06309355 · ClinicalTrials.gov registry record · Phase 2
Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Hangzhou Yirui Pharmaceutical Technology Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 4
- Study locations
NCT06309355 is a Phase 2 study of Atopic Dermatitis that has completed, run by Hangzhou Yirui Pharmaceutical Technology Co.. The registered enrollment target is 35 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT06309355, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Hangzhou Yirui Pharmaceutical Technology Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in adult patients with mild to moderate atopic dermatitis
Conditions Studied
Interventions
- OTHER Placebo
- DRUG YR001 ointment
Study Locations (4)
Florida
- Encore Medical Research -Boynton Beach - Boynton Beach
- Encore Medical Research-Hollywood - Hollywood
- Encore Medical Research-Weston - Weston
Louisiana
- DelRicht Research - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2025-11-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06309355
The ClinicalTrials.gov registry entry for NCT06309355 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (94% lower). The listed sponsor is Hangzhou Yirui Pharmaceutical Technology Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06309355 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT06309355 about?
NCT06309355 is a clinical study titled "Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis". This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in adult patients with mild to moderate atopic dermatitis
What is the current status of trial NCT06309355?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2024-06-19. Estimated completion is 2025-11-20.
What conditions does trial NCT06309355 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06309355?
The interventions under investigation include: Placebo (OTHER), YR001 ointment (DRUG).
Who is sponsoring clinical trial NCT06309355?
This trial is sponsored by Hangzhou Yirui Pharmaceutical Technology Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06309355 being conducted?
This trial has 4 study locations across Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.